Posted by Michael Wonder on 08 Jan 2020
ReNetX Bio receives fast track designation from U.S. FDA
8 January 2020 - Potential first-in-class therapy for chronic spinal cord injury.
ReNetX Bio announced today that the U.S. FDA has granted the company fast track designation for ReNetX Bio’s clinical therapy (AXER-204) for the potential treatment of chronic spinal cord injury.
ReNetX Bio is currently conducting a Phase 1/2 clinical trial “RESET” in patients with SCI, with top-line results expected in 2021.
